Source-grounded facts extracted from Merck & Co., Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Merck & Co., Inc. reported first quarter of 2026 results: revenue $16,286, net income (4,240), EPS (1.72). Guidance raised.
“First Quarter $ in millions, except EPS amounts 2026 2025 Change Change Ex- Exchange Sales $ 16,286 $ 15,529 5 % 3 % GAAP net (loss) income 2 (4,240 ) 5,079 N/M N/M Non-GAAP net (loss) income that excludes certain items 2,3* (3,156 ) 5,611 N/M N/M GAAP EPS (1.72 ) 2.01 N/M N/M”
Merck & Co., Inc. announced a restructuring with charges of approximately $3.0 billion affecting sales and administrative organizations, research and development, global real estate footprint, manufacturing network.
“expected to be substantially completed by the end of 2029. The cumulative pretax costs to be incurred by the Company to implement the program are estimated to be approximately $3.0 billion, of which approximately 60% will be cash, relating primarily to employee separation expense and contractual termination costs. The remainder of the costs will be non-cash,”
Surendralal L. “Lal” Karsanbhai was elected as Director at Merck & Co., Inc..
“announcing the election of Surendralal L. “Lal” Karsanbhai to the Company’s Board of Directors (the “Board”), effective January 1, 2025.”
Merck & Co., Inc. reported first quarter of 2024 results: revenue $15,775, net income 4,762, EPS GAAP EPS 1.87; Non-GAAP EPS that excludes certain items 2* 2.07. Guidance raised.
“Financial Summary First Quarter $ in millions, except EPS amounts 2024 2023 Change Change Ex- Exchange Sales $ 15,775 $ 14,487 9 % 12 % GAAP net income 1 4,762 2,821 69 % 76 % Non-GAAP net income that excludes certain items 1,2* 5,279 3,564 48 % 54 % GAAP EPS 1.87 1.11 68 % 76 % Non-GAAP EPS that excludes certain items 2* 2.07 1.40 48 % 54 %”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.